Sol-Gel Technologies (SLGL) EPS (Weighted Average and Diluted) (2019 - 2025)
Sol-Gel Technologies (SLGL) reported EPS (Weighted Average and Diluted) of -$1.22 for Q4 2025, up 44.07% year-over-year from -$0.85 in Q4 2024, and down 129.36% quarter-over-quarter from $4.17 in Q2 2025.
Sol-Gel Technologies (SLGL) EPS (Weighted Average and Diluted) (2019 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.22 in Q4 2025.
- EPS (Weighted Average and Diluted) for Q4 2025 came in at -$1.22, up 44.07% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.22 (up 44.07% YoY), and the FY2025 annual result was -$2.19, up 42.22% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$1.22 in Q4 2025 per SLGL's latest filing, from $4.17 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $4.17 in Q2 2025 and troughed at -$2.19 in Q4 2024.
- A 5-year average of $0.03 and a median of $0.03 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 2100.0% in 2023 and fell as far as 698.46% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.61 in 2021, then plunged by 140.98% to -$0.25 in 2022, then slumped by 698.46% to -$2.0 in 2023, then decreased by 9.68% to -$2.19 in 2024, then soared by 44.07% to -$1.22 in 2025.
- Business Quant data shows SLGL's EPS (Weighted Average and Diluted) at -$1.22 in Q4 2025, $4.17 in Q2 2025, and -$2.19 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.22 |
| Jun 30, 2025 | 4.17 |
| Dec 31, 2024 | -2.19 |
| Jun 30, 2024 | 0.71 |
| Dec 31, 2023 | -2.00 |
| Jun 30, 2023 | 0.22 |
| Dec 31, 2022 | -0.25 |
| Sep 30, 2022 | -0.15 |
| Jun 30, 2022 | 0.01 |
| Dec 31, 2021 | 0.61 |
| Sep 30, 2021 | 0.05 |
| Jun 30, 2021 | 0.35 |
| Dec 31, 2020 | -0.28 |
| Sep 30, 2020 | -0.37 |
| Dec 31, 2019 | -2.31 |